Samba

Samba BioLogics is a pre-clinical stage biotechnology company focused on developing breakthrough agonist biologics for regenerative medicine and tissue repair. Founded in 2012 and based in Vermont, the company leverages its proprietary platform to design therapies that preserve tissue and improve repair after ischemic injuries, such as myocardial infarction. Its pipeline features Cell-Kro, a combination of connective tissue growth factor domain 4 (CTGF-D4) and insulin designed to prime progenitor cells for successful engraftment, and VasaPlex, a hepatocyte growth factor (HGF) and immunoglobulin G (IgG) complex aimed at rescuing cardiac tissue from reperfusion injury. Samba BioLogics' innovative approaches aim to address critical unmet needs in cardiovascular disease and regenerative therapeutics.